The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?

Feb 1, 2020

The Lymphoma Hub are pleased to present a series of expert interviews from the 2nd European CAR T Cell Meeting in Sitges, ES. In this video, Javier Briones from Hospital de la Santa Creu i Sant Pau, Barcelona, ES, explains why we should use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma.

Javier Briones explains CAR T therapy for Non-Hodgkin lymphoma and B-cell malignancies have shown to be effective but this success has not translated to Hodgkin lymphoma. He discusses his new trial that will look into the generation of CAR products directed at CD30, that are rich in memory T cells with greater intratumor activity.

Why should we use CAR30 memory T cells to treat Hodgkin and T-cell lymphoma?